塞罗利斯作为对中度至重度慢性移植与宿主疾病的皮质类固醇的附加治疗
Ritika Sharma1, Andrew Pardeep1, Renaissa De1
1Clinical Hematology & Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Blood cell therapy
|December 9, 2024
概括
当添加到皮质类固醇时,西洛利木斯有效控制了中度至严重的慢性移植对宿主疾病 (cGVHD). 这种治疗方法为皮质类固醇耐药/依赖cGVHD的患者提供了可行的选择.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 中度至严重的慢性移植对宿主疾病 (cGVHD) 的一线治疗通常涉及全身皮质类固醇,通常与氨酸抑制剂结合.
- 大约一半的cGVHD患者需要二线治疗,原因是皮质类固醇耐药/依赖性 (SR/SD) 疾病.
研究的目的:
- 评估西洛斯作为对皮质类固醇的补充疗法的安全性和有效性,用于管理中度至重度cGVHD.
- 评估西洛斯对SR/SDcGVHD患者疾病控制和生存的影响.
主要方法:
- 一项单中心研究包括12岁或以上的全基细胞移植接受者,他们在2016年至2022年期间被诊断出中度至重度cGVHD.
- 在医生的裁量下,西洛利木斯作为中度至重度cGVHD的皮质类固醇的补充剂,使用EBMT-NIH-CIBMTR标准评估反应.
主要成果:
- 在134名接受者中,53人患有中度至重度cGVHD,38人 (71.6%) 接受了西洛. 在6个月后,cGVHD在79%的患者中得到控制.
- 最常见的不良事件是脂质不良 (73%). 两年无故障生存率为61%.
结论:
- 赛洛斯证明了作为适度至重度cGVHD系统性皮质类固醇的补充剂的安全性和有效性.
- 这种治疗策略有望减少SR/SD cGVHD的负担,改善患者的治疗结果.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95